Isturisa
Manufacturing · United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.isturisa.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Isturisa
Recordati Rare Diseases Inc. offers ISTURISA® (osilodrostat), the first FDA-approved oral treatment for adults with Cushing's disease, specifically for those who cannot undergo surgery or have not been cured by previous surgeries. The medication works by blocking an enzyme that produces cortisol, helping patients achieve and maintain normal cortisol levels. The company provides extensive patient support resources, including individualized dosing guidance and a patient liaison program. Their primary clients are adults diagnosed with Cushing's syndrome and their caregivers.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Isturisa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Isturisa recently announced quarterly report
Check if Isturisa has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Isturisa
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Isturisa launches new products
Funding: Get notified immidiatlly once Isturisa has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Isturisa had a recent Job posting/layoffs
Isturisa, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Isturisa is spiking on competitors!
Recommended Actions
Find VP level buyers at Isturisa
Find 3 more new buyers
Compare Similar Companies to Isturisa
Compare insights from companies similar to Isturisa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
Isturisa is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Isturisa is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Isturisa.
Isturisa Tech Stack
A closer look at the technologies used by Isturisa
See more technologies
Isturisa News & Media
Recordati Rare Diseases Announces Several Scientific Abstracts to Be Presented at the Upcoming Endo Society Annual Meeting
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June 11 – 14, 2022. Recordati will be exhibiting at booth #821. Key Onsite Abstract Presentations: Monday, June 13, 12:30 PM - 2:30 PM Richard Auchus, MD - Management, Safety, and Efficacy of Osilodrostat Treatment in US patients with non-pituitary Cushing’s Syndrome: ResPhase III LINC 3 Study Demonstrates That ISTURISA® (osilodrostat) Improves Physical Features Associated With Hypercortisolism in Patients With Cushing’s Disease
LEBANON, N.J.--(BUSINESS WIRE)--AACE Post-Presentation ReleaseRecordati Rare Diseases Announces Multiple Scientific Abstracts to Be Highlighted at American Association of Clinical Endocrinology
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be featured onsite at the American Association of Clinical Endocrinology (AACE) annual meeting being held in San Diego, California from May 12 – 14, 2022. Recordati will be exhibiting at booth #122. Key Onsite abstracts presented by Alberto Pedroncelli MD, Head of Clinical Development & Medical Affairs, Global Endocrinology, Recordati AG. All times listeRecordati Rare Diseases Announce Publication in The Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming Efficacy and Safety of ISTURISA® (osilodrostat) in Patients With Cushing’s Disease
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. announce today the publication of positive results from the Phase III LINC 4 study of ISTURISA in The Journal of Clinical Endocrinology & Metabolism.1 These data reinforce ISTURISA as an effective and well-tolerated oral therapy for patients with Cushing’s disease. ISTURISA is indicated in the United States for the treatment of adult patients with Cushing’s disease,2 a rare and debilitating condition of hypercortisolism that is ca
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Isturisa
Sign Up For FreeTo access detailed company insights
Recordati Rare Diseases Inc. offers ISTURISA® (osilodrostat), the first FDA-approved oral treatment for adults with Cushing's disease, specifically for those who cannot undergo surgery or have not been cured by previous surgeries. The medication works by blocking an enzyme that produces cortisol, helping patients achieve and maintain normal cortiso... Read More
